Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Shares of early-stage biotech stocks, including Biohaven (NYSE: BHVN), Recursion Pharmaceuticals (NASDAQ: RXRX), and CRISPR Therapeutics (NASDAQ: CRSP), plunged in March, with the stocks down 35.3%, ...

CRISPR Therapeutics AG (NASDAQ:CRSP) reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease. The company disclosed data regarding the first 10 ...

-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with ...

They look like ordinary horses, with their honey brown coats and white patches. But these 10-month-old foals in Argentina are the world's first gene-edited horses, according to scientists. Experts say ...

Biotechnology is revolutionizing industries and transforming human health worldwide. Today’s biotech leaders must bridge laboratory breakthroughs with business strategy to bring life-changing ...